In vitro activity of BMY-28100, a new oral cephalosporin.
BMY-28100 is a new orally absorbed cephalosporin whose in vitro activity was compared with that of cefaclor. BMY-28100 was more active against Staphylococcus aureus and Haemophilus influenzae than was cefaclor. In addition, there was only a small rise in MIC50 and MIC90 values for BMY-28100 when the inoculum size was increased 100- or 10,000-fold. In contrast, MIC50 and MIC90 values increased significantly for cefaclor with similar increases in inoculum size. These data suggest that BMY-28100 may be a promising agent to test for oral administration in infections caused by S. aureus and H. influenzae.
Norden
C W
CW
Montefiore Hospital, Department of Medicine, University of Pittsburgh, School of Medicine, Pa.
Niederriter
K
K
D002433:Cefaclor / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D006193:Haemophilus influenzae / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects*; D000097670:Cefprozil
D002433:Cefaclor; D002511:Cephalosporins; D000097670:Cefprozil